boston.com Your Life your connection to The Boston Globe
White Coat Notes: News from the Boston-area medical community
Comments
Send your comments and tips to whitecoat@globe.com
Categories


Blogger
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Contributors
Boston Globe Health and Science staff:
Scott Allen
Alice Dembner
Carey Goldberg
Liz Kowalczyk
Stephen Smith
Colin Nickerson
Beth Daley
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
 Short White Coat blogger Ishani Ganguli
 Short White Coat blogger Jennifer Srygley
Week of: November 11
Week of: November 4
Week of: October 28
Week of: October 21
Week of: October 14
Week of: October 7

« BU names NIH official to major biolab post | Main | More get insurance »

Thursday, September 13, 2007

Combining targeted drugs may work better against brain tumors, study says

Aggressive brain tumors receive more than one chemical signal telling them to grow, so more than one targeted drug should be used to shut these switches down, Dana-Farber researchers report.

Writing in the online edition of the journal Science, Dr. Ronald DePinho and his colleagues say they found many kinds of mutated cell-growth molecules sending abnormal signals at the same time, explaining why drugs such as Gleevec that target only one signaling pathway have only limited success.

The researchers were studying cells from glioblastoma multiforme, the most common kind of brain tumor and one of the most lethal forms of cancer people can have. The median survival time is about 12 months.

Testing a combination of three or more drugs, including Tarceva and Gleevec, the authors discovered they were able to block the abnormal signals and kill the cancer cells.

The authors recommend clinical trials to see if a combination of Gleevec, Tarceva and other compounds can thwart tumor cell growth. They also note that the signaling patterns they saw in brain tumors have been detected in cell lines of two other kinds of cancer with poor survival rates: lung and pancreatic.

And based on what they called proof-of-principle for personalized medicine, they suggest studying patients' tumor cells to see which switches are activated so the best drugs to block them can be used.

Posted by Elizabeth Cooney at 02:00 PM
Sponsored Links